BRPI1007334A2 - composto, inibidor, medicamento, composição farmacêutica, uso de um composto, agente anticâncer,e , método para tratar câncer. - Google Patents

composto, inibidor, medicamento, composição farmacêutica, uso de um composto, agente anticâncer,e , método para tratar câncer.

Info

Publication number
BRPI1007334A2
BRPI1007334A2 BRPI1007334A BRPI1007334A BRPI1007334A2 BR PI1007334 A2 BRPI1007334 A2 BR PI1007334A2 BR PI1007334 A BRPI1007334 A BR PI1007334A BR PI1007334 A BRPI1007334 A BR PI1007334A BR PI1007334 A2 BRPI1007334 A2 BR PI1007334A2
Authority
BR
Brazil
Prior art keywords
compound
inhibitor
drug
pharmaceutical composition
treating cancer
Prior art date
Application number
BRPI1007334A
Other languages
English (en)
Inventor
Hiroyuki Naito
Kouichi Uoto
Keisuke Yoshida
Masaki Miyazaki
Masashi Aonuma
Yuuichi Sugimoto
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of BRPI1007334A2 publication Critical patent/BRPI1007334A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/499—Spiro-condensed pyrazines or piperazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyrrole Compounds (AREA)
BRPI1007334A 2009-01-16 2010-01-15 composto, inibidor, medicamento, composição farmacêutica, uso de um composto, agente anticâncer,e , método para tratar câncer. BRPI1007334A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009007536 2009-01-16
PCT/JP2010/050372 WO2010082612A1 (ja) 2009-01-16 2010-01-15 プロリン環構造を有するイミダゾチアゾール誘導体

Publications (1)

Publication Number Publication Date
BRPI1007334A2 true BRPI1007334A2 (pt) 2016-02-10

Family

ID=42339866

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1007334A BRPI1007334A2 (pt) 2009-01-16 2010-01-15 composto, inibidor, medicamento, composição farmacêutica, uso de um composto, agente anticâncer,e , método para tratar câncer.

Country Status (24)

Country Link
US (2) US8404691B2 (pt)
EP (1) EP2380892B1 (pt)
JP (1) JP5520236B2 (pt)
KR (1) KR20110119641A (pt)
CN (1) CN102356085A (pt)
AU (1) AU2010205201A1 (pt)
BR (1) BRPI1007334A2 (pt)
CA (1) CA2750009A1 (pt)
CO (1) CO6420347A2 (pt)
CY (1) CY1115234T1 (pt)
DK (1) DK2380892T3 (pt)
ES (1) ES2463820T3 (pt)
HR (1) HRP20140409T1 (pt)
IL (1) IL214117A0 (pt)
MX (1) MX2011007598A (pt)
PL (1) PL2380892T3 (pt)
PT (1) PT2380892E (pt)
RU (1) RU2011134283A (pt)
SG (1) SG173028A1 (pt)
SI (1) SI2380892T1 (pt)
SM (1) SMT201400082B (pt)
TW (1) TW201030011A (pt)
WO (1) WO2010082612A1 (pt)
ZA (1) ZA201105132B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2009151069A1 (ja) * 2008-06-12 2011-11-17 第一三共株式会社 ４，７−ジアザスピロ［２．５］オクタン環構造を有するイミダゾチアゾール誘導体
TR201807311T4 (tr) 2011-03-10 2018-06-21 Daiichi Sankyo Co Ltd Dispiropirolidin derivesi.
TWI586668B (zh) 2012-09-06 2017-06-11 第一三共股份有限公司 二螺吡咯啶衍生物之結晶
JP2017532959A (ja) * 2014-10-09 2017-11-09 第一三共株式会社 Ｍｄｍ２阻害剤に対する感受性の遺伝子シグネチャーに基づく予測因子に関するアルゴリズム
CN109152843A (zh) 2016-05-20 2019-01-04 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法
EP3360865A1 (en) 2017-02-13 2018-08-15 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Process for the preparation of cyclopropyldiketopiperazines, and of a key intermediate of ds-5272
CN111943894A (zh) * 2019-05-17 2020-11-17 南京爱德程医药科技有限公司 一种4,7-二氮杂螺[2.5]辛烷类化合物的合成方法
WO2022183006A1 (en) 2021-02-25 2022-09-01 Mayo Foundation For Medical Education And Research Compounds for programmable protein degradation and methods of use for the disease treatment
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000072743A (ja) 1998-08-31 2000-03-07 Japan Science & Technology Corp アルケンのアジリジン化法
US6979551B2 (en) 2000-04-03 2005-12-27 Rigel Pharmaceuticals, Inc. Assays for identifying ubiquitin agents and for identifying agents that modify the activity of ubiquitin agents
US6740495B1 (en) 2000-04-03 2004-05-25 Rigel Pharmaceuticals, Inc. Ubiquitin ligase assay
JP4361798B2 (ja) 2001-12-18 2009-11-11 エフ．ホフマン−ラ ロシュ アーゲー Ｍｄｍ２インヒビターとしてのシス−イミダゾリン
KR100650966B1 (ko) 2001-12-18 2006-11-30 에프. 호프만-라 로슈 아게 시스-2,4,5-트리페닐-이미다졸린 및 종양 치료에서의 그의용도
MXPA05013465A (es) 2003-06-17 2006-03-09 Hoffmann La Roche Cis-imidazolinas como inhibidores de mdm2.
US7132421B2 (en) 2003-06-17 2006-11-07 Hoffmann-La Roche Inc. CIS-imidazoles
WO2005003097A1 (en) 2003-06-17 2005-01-13 F. Hoffmann-La Roche Ag Cis-2,4,5-triaryl-imidazolines
US7425638B2 (en) 2003-06-17 2008-09-16 Hoffmann-La Roche Inc. Cis-imidazolines
GB0324498D0 (en) 2003-07-21 2003-11-26 Aventis Pharma Inc Heterocyclic compounds as P2X7 ion channel blockers
JP2005075754A (ja) 2003-08-29 2005-03-24 Mitsui Chemicals Inc トランス−１，２−ビス（３，５−ジメチルフェニル）−１，２−エタンジアミンの光学分割方法
KR20080027969A (ko) 2004-05-18 2008-03-28 에프. 호프만-라 로슈 아게 신규 ｃｉｓ-이미다졸린
US7893278B2 (en) 2004-06-17 2011-02-22 Hoffman-La Roche Inc. CIS-imidazolines
CN101316823B (zh) 2005-12-01 2013-05-22 霍夫曼-拉罗奇有限公司 用作抗癌剂的作为p53和MDM2蛋白之间相互作用的抑制剂的2,4,5-三苯基咪唑啉衍生物
CN101605798A (zh) * 2006-12-14 2009-12-16 第一三共株式会社 咪唑并噻唑衍生物
JP5019102B2 (ja) * 2006-12-14 2012-09-05 東芝機械株式会社 ガラス成形用金型の製造方法
BRPI0810082A2 (pt) * 2007-03-29 2014-10-21 Novartis Ag 3-imidazolil-indóis para o tratamento de doenças proliferativas
US7625895B2 (en) 2007-04-12 2009-12-01 Hoffmann-Le Roche Inc. Diphenyl-dihydro-imidazopyridinones
JP2009298713A (ja) * 2008-06-11 2009-12-24 Daiichi Sankyo Co Ltd イミダゾチアゾール誘導体
JPWO2009151069A1 (ja) 2008-06-12 2011-11-17 第一三共株式会社 ４，７−ジアザスピロ［２．５］オクタン環構造を有するイミダゾチアゾール誘導体

Also Published As

Publication number Publication date
PL2380892T3 (pl) 2014-08-29
ES2463820T3 (es) 2014-05-29
CA2750009A1 (en) 2010-07-22
JPWO2010082612A1 (ja) 2012-07-05
CY1115234T1 (el) 2017-01-04
TW201030011A (en) 2010-08-16
ZA201105132B (en) 2012-03-28
EP2380892A1 (en) 2011-10-26
US20110301176A1 (en) 2011-12-08
SMT201400082B (it) 2014-09-08
JP5520236B2 (ja) 2014-06-11
SG173028A1 (en) 2011-08-29
RU2011134283A (ru) 2013-02-27
WO2010082612A1 (ja) 2010-07-22
EP2380892B1 (en) 2014-04-02
PT2380892E (pt) 2014-06-09
AU2010205201A1 (en) 2011-08-04
EP2380892A4 (en) 2012-08-29
US20130172362A1 (en) 2013-07-04
IL214117A0 (en) 2011-08-31
HRP20140409T1 (hr) 2014-06-06
KR20110119641A (ko) 2011-11-02
US8404691B2 (en) 2013-03-26
SI2380892T1 (sl) 2014-05-30
MX2011007598A (es) 2011-08-08
CN102356085A (zh) 2012-02-15
DK2380892T3 (da) 2014-06-30
CO6420347A2 (es) 2012-04-16

Similar Documents

Publication Publication Date Title
BR112013023175A2 (pt) composto, inibidor, medicamento, agente anticâncer, composição farmacêutica, método para o tratamento de câncer, e, uso de um composto
BRPI0922475A2 (pt) composto, composição farmacêutica , método para tratar câncer, e, uso de um composto.
BRPI0720546A2 (pt) Composto, inibidor, medicamento, agente antitumor, composição farmacêutica, método para tratar câncer, e, uso do composto
BRPI1015983A2 (pt) composto, uso do composto, método para tratar um paciente, e, composição farmacêutica.
BRPI0906576A2 (pt) Composição farmacêutica, kit, uso de um composto, e, agente terapêutico para câncer
BR112012018951A2 (pt) composição farmacêutica, combinação farmacêutica e método para o tratamento e\ou prevenção de um câncer e anticorpo
CL2011002595A1 (es) Uso de una combinacion de un agente anticancerigeno y un antioxidante para tratar el cancer; y compicicion farmaceutica que comprende dicha combinacion.
BRPI0914927A2 (pt) composto, composição farmacêutica, métodos para inibir a função de fak e de tratamento de um câncer, uso de um composto, e, processo para preparar um composto
BRPI0917458A2 (pt) composto, método de tratamento de doenças e condições, composição farmacêutica, método para tratar ou prevenir doença, e, uso de um composto
BRPI0907977A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças
BRPI1008383A2 (pt) composto, composição farmacêutica, método para prevenir, inibir ou tratar uma condição, e, uso de um composto
BR112012018947A8 (pt) composição farmacêutica para o tratamento e/ou prevenção de um câncer, anticorpo, combinação farmacêutica e método para o tratamento e/ou prevenção de um câncer
BRPI0818426A2 (pt) produto de combinação, uso de um produto de combinação, e, método para tratar câncer
BRPI1010937A2 (pt) composto, uso de um composto, e, método para tratar câncer
BRPI0814777A2 (pt) Composto, composição farmacêutica, método para tratar um neoplasma, uso de um composto, e, composição farmacêutica.
BR112012026570A2 (pt) composto, composição farmacêutica, uso de um composto, método para o tratamento de um indíviduo e produto combinado
BR112015004547A8 (pt) compostos, composição farmacêutica, uso de um composto e método para o tratamento ou melhoria do cãncer
BRPI0908100A2 (pt) produto combinação, uso de um composto, e, método de tratar câncer
BRPI0907974A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças
CL2007003331A1 (es) Metodo para tratar cancer mediante la administracion de un agente radiosensibilizante derivado de benzo[a]trinden-4,6-diona; composicion farmaceutica que comprende dicho agente.
BR112014030416A2 (pt) composto, métodos para a inibição da tankyrase 1 e para o tratamento do câncer, utilização de um composto, composição e invenção.
BRPI0818323A2 (pt) composição farmacêutica, uso de uma composição farmacêutica, e, método para tratar câncer.
BR112014032053A2 (pt) composto, composição farmacêutica, utilização de um composto, método para o tratamento de câncer e invenção
BRPI0908635A2 (pt) composto, composição farmacêutica e método de tratamento de câncer
BR112015000649A2 (pt) compostos, composição farmacêutica, uso de um composto, método para tratar ou melhorar câncer e invenção

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]